Pilot Study of Thalidomide to Treat Sjogren's Syndrome
Launched by NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR) · Nov 3, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
Sjogren's syndrome (SS) is a systemic autoimmune disease that predominantly affects women. SS is characterized by lymphocytic infiltration of lacrimal and salivary glands leading to secretory function loss, and the symptoms of dry eyes and dry mouth. After bone marrow transplantation, most patients with chronic graft versus host disease (GVHD) develop symptoms of oral dryness and salivary gland lymphocytic infiltrates indistinguishable from SS. Thalidomide has not been studied as a treatment for Sjogren's syndrome, but pilot studies suggest that it may be beneficial in the treatment of a nu...
Gender
FEMALE
Eligibility criteria
- • Primary Sjogren's Syndrome; symptoms of dry eyes and dry mouth; 6 week period off disease modifying agents, such as antimalarials or steroids.
- • No males.
- • No females with childbearing potential.
- • No patients with hypersensitivity to thalidomide.
- • No confounding medical illness or abnormal laboratory test that in the judgment of the investigators would pose added risk for study participants.
About National Institute Of Dental And Craniofacial Research (Nidcr)
The National Institute of Dental and Craniofacial Research (NIDCR) is a pivotal component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of dental and craniofacial disorders. Through innovative research and clinical trials, NIDCR aims to enhance oral health and improve the quality of life for individuals affected by these conditions. The institute fosters collaboration among scientists, clinicians, and public health professionals to translate research findings into practical applications, ensuring that the latest advancements benefit patients and communities. With a commitment to excellence in research and education, NIDCR plays a critical role in shaping the future of oral health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials